Heng B. See

Perth, WA, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Novel Pharmacology Following Heteromerization of the Angiotensin II Type 2 Receptor and the Bradykinin Type 2 Receptor.

Novel Pharmacology Following Heteromerization of the Angiotensin II Type 2 Receptor and the Bradykinin Type 2 Receptor.

Journal: Frontiers in endocrinology
Published: January 05, 2022

Complex interactions between the angiotensin II type 1 receptor, the epidermal growth factor receptor and TRIO-dependent signaling partners.

Complex interactions between the angiotensin II type 1 receptor, the epidermal growth factor receptor and TRIO-dependent signaling partners.

Journal: Biochemical pharmacology
Published: January 12, 2021

Investigation of Receptor Heteromers Using NanoBRET Ligand Binding.

Investigation of Receptor Heteromers Using NanoBRET Ligand Binding.

Journal: International journal of molecular sciences
Published: January 04, 2021

The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.

The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprograming in estrogen receptor-positive breast cancer.

Journal: Nature communications
Published: October 31, 2020

Insights into the Interaction of LVV-Hemorphin-7 with Angiotensin II Type 1 Receptor.

Insights into the Interaction of LVV-Hemorphin-7 with Angiotensin II Type 1 Receptor.

Journal: International journal of molecular sciences
Published: October 29, 2020

Disease-associated missense variants in ZBTB18 disrupt DNA binding and impair the development of neurons within the embryonic cerebral cortex.

Disease-associated missense variants in ZBTB18 disrupt DNA binding and impair the development of neurons within the embryonic cerebral cortex.

Journal: Human mutation
Published: December 19, 2018

NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing.

NanoBRET ligand binding at a GPCR under endogenous promotion facilitated by CRISPR/Cas9 genome editing.

Journal: Cellular signalling
Published: September 02, 2018

Using nanoBRET and CRISPR/Cas9 to monitor proximity to a genome-edited protein in real-time.

Using nanoBRET and CRISPR/Cas9 to monitor proximity to a genome-edited protein in real-time.

Journal: Scientific reports
Published: December 09, 2016

Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking.

Mutations of Vasopressin Receptor 2 Including Novel L312S Have Differential Effects on Trafficking.

Journal: Molecular endocrinology (Baltimore, Md.)
Published: June 30, 2016

i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.

i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.

Journal: The Journal of biological chemistry
Published: February 10, 2016

Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease.

Functional interaction between angiotensin II receptor type 1 and chemokine (C-C motif) receptor 2 with implications for chronic kidney disease.

Journal: PloS one
Published: December 06, 2014

Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.

Profiling epidermal growth factor receptor and heregulin receptor 3 heteromerization using receptor tyrosine kinase heteromer investigation technology.

Journal: PloS one
Published: February 03, 2013
Showing 1-12 of 13

Last Updated: 09/26/2026